findmyKOL
Clinical trialNCT04146376RecruitingObservational

Von Willebrand Factor in Pregnancy (VIP) Study

SponsorUniversity of WashingtonEnrollment110Von Willebrand Diseases
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Colorado

    Aurora, Colorado, United States

    Genevieve Moyer, MD
    Recruiting
  • Yale University

    New Haven, Connecticut, United States

    Robert Bona, MD
    Recruiting
  • University of Miami

    Miami, Florida, United States

    Michael Paidas, MD
    Recruiting
  • Emory University

    Atlanta, Georgia, United States

    Christine Kempton, MD, MSc
    Recruiting
  • Bleeding & Clotting Disorders Institute

    Peoria, Illinois, United States

    Jonathan Roberts, MD
    Recruiting
  • Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders

    New Orleans, Louisiana, United States

    Maissaa Janbain, MD
    Recruiting
  • Oregon Health & Science University

    Portland, Oregon, United States

    Withdrawn
  • the Pennsylvania State University

    Hershey, Pennsylvania, United States

    Peter Cygan, MD
    Recruiting
  • Vanderbilt University

    Nashville, Tennessee, United States

    Shannon Walker, MD
    Recruiting
  • University of Utah

    Salt Lake City, Utah, United States

    Ming Lim, MBBCh, MS
    Recruiting
  • Washington Center for Bleeding Disorders

    Seattle, Washington, United States

    Allison Wheeler, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tranexamic acid →VWF replacement therapy with Wilate
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Oct 2019
Primary completion
31 Dec 2026
Completion
31 Dec 2026
Last update posted
18 Dec 2025
Registered enrollment
110
Registry id
NCT04146376
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.